|1.||Bauss, Frieder: 18 articles (12/2015 - 01/2003)|
|2.||Reginster, Jean-Yves: 13 articles (06/2014 - 08/2005)|
|3.||Body, Jean-Jacques: 13 articles (01/2008 - 09/2004)|
|4.||Felsenberg, Dieter: 9 articles (04/2015 - 08/2004)|
|5.||Miller, Paul D: 9 articles (10/2013 - 03/2005)|
|6.||Bauss, F: 9 articles (12/2011 - 01/2000)|
|7.||Body, J J: 9 articles (11/2011 - 06/2000)|
|8.||Delmas, Pierre D: 9 articles (04/2009 - 05/2002)|
|9.||Christiansen, C: 9 articles (05/2006 - 10/2001)|
|10.||Hashimoto, Junko: 8 articles (12/2015 - 01/2007)|
06/01/2014 - "Excellent pain reduction (pain at rest and under strain) and improved mobility was reported within the first two weeks after the first ibandronate administration by sixteen patients (64%). "
01/01/2013 - "Bonviva therapy results in a significant reduction in pain, KJ stiffness, and locomotor functional failure in patients with gonoarthrosis."
01/01/2010 - "The EQ-5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). "
11/01/2004 - "Ibandronate has also been shown to provide significant and sustained relief from metastatic bone pain over 2 years of treatment, improving patient functioning and quality of life. "
12/01/2012 - "In this pilot study, we investigated the therapeutic efficacy of intravenous Ibandronate compared to pain medication on the outcome of bone marrow edemas (BME) of the knee and talus. "
01/01/2012 - "Hip structural analysis (HSA) performed in a subset of participants from the STudy Researching Osteoporosis iN Guys (STRONG) demonstrated that 1 year of ibandronate treatment was associated with a significant improvement in some but not all parameters of hip geometry relative to placebo in men with low bone density. "
09/01/2009 - "After the Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) study had demonstrated the strong vertebral and nonvertebral antifracture efficacy of daily and intermittent oral ibandronate, the Monthly Oral Ibandronate In Ladies (MOBILE) study gave evidence for an increased efficacy on the bone mineral density (BMD) of higher intermittent oral ibandronate doses (150 mg monthly) compared with 2.5 mg daily. "
04/01/2008 - "A significantly greater proportion of participants who selected intravenous versus oral treatment had a primary diagnosis of osteoporosis (72.2% vs 57.1%, respectively; P<0.001) and a history of fracture as an adult (35.6% vs 22.4%; P >or= 0.004); significantly fewer recipients of intravenous versus oral ibandronate were currently working (29.0% vs 39.5%; P >or= 0.021). "
11/01/2012 - "The objective of this study is to evaluate the efficacy of ibandronate (IBN) in prevention and treatment of glucocorticoid-induced osteoporosis in rabbits. "
05/01/2006 - "Early clinical trials demonstrated efficacy and tolerability of intravenous ibandronate in the prevention or treatment of postmenopausal and corticosteroid-associated osteoporosis when administered once every 3 months. "
04/01/2008 - "This meticulous methodology provided a highly effective means of identifying vertebral fractures and recruiting the trial population in which to assess the efficacy of ibandronate in postmenopausal osteoporosis."
01/01/2005 - "These simple ibandronate regimens are expected to provide the optimal combination of efficacy, tolerability and patient convenience, leading to improved treatment adherence and thus, enhanced outcomes in postmenopausal osteoporosis."
08/01/2008 - "In conclusion, 150-mg monthly oral ibandronate is an effective and well-tolerated long-term treatment for postmenopausal osteoporosis, with consistent improvement in BMD and bone turnover during 3 years' continuous treatment."
04/01/2006 - "Once-monthly ibandronate is an effective and well-tolerated treatment option for postmenopausal osteoporosis."
04/01/2006 - "Once-monthly ibandronate is an effective and well-tolerated treatment for patients with postmenopausal osteoporosis. "
|4.||Breast Neoplasms (Breast Cancer)
11/01/2009 - "Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer."
10/01/2013 - "German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer."
01/01/2006 - "Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial."
01/01/2006 - "Our in vitro study examined the cytotoxic effects resulting from combinations of ibandronate and ionising radiations (RX) in various sequences on breast cancer cells. "
01/01/2005 - "In a 2-year, phase III study of patients with breast cancer metastatic to bone, the incidence of adverse renal events in patients treated with 6 mg i.v. ibandronate was low and comparable with that of placebo (4% versus 4.5% with placebo). "
|5.||Bone Diseases (Bone Disease)
12/01/2004 - "With its favorable efficacy and safety profile, and the added convenience of the oral formulation, ibandronate provides improved treatment options for managing metastatic bone disease."
11/01/2007 - "These results indicate that ibandronate may be an effective treatment for patients with metastatic bone disease following CRC. "
05/01/2004 - "Oral ibandronate is an effective and well-tolerated treatment for metastatic bone disease. "
01/01/2005 - "Efficacy of ibandronate in metastatic bone disease: review of clinical data."
10/01/2010 - "This interim analysis of a prospective non-interventional study documents the efficacy and safety of the amino-bisphosphonate ibandronate in the treatment of metastatic bone disease under real-life conditions. "
|1.||ibandronic acid (Boniva)
|3.||zoledronic acid (zoledronate)
|5.||Alendronate (Alendronate Sodium)
|7.||Clodronic Acid (Clodronate)
|8.||risedronic acid (risedronate)
|10.||Sodium Fluoride (Ossin)